The standardized EuroFlow protocol, including CD19 as primary B-cell marker, enables highly sensitive and reliable minimal residual disease (MRD) assessment in B-cell precursor acute lymphoblastic leukaemia (BCP-ALL) patients treated with chemotherapy. We developed and validated an alternative gating strategy allowing reliable MRD analysis in BCP-ALL patients treated with CD19-targeting therapies. Concordant data were obtained in 92% of targeted therapy patients who remained CD19-positive, whereas this was 81% in patients that became (partially) CD19-negative. Nevertheless, in both groups median MRD values showed excellent correlation with the original MRD data, indicating that, despite higher interlaboratory variation, the overall MRD analysis was correct.

Biomedical Research Networking Centre Consortium of Oncology Instituto de Salud Carlos 3 Madrid Spain

CLIP Department of Pediatric Hematology and Oncology 2nd Faculty of Medicine Charles University and University Hospital Motol Prague Czech Republic

Department of Diagnostic Sciences Ghent University Ghent Belgium

Department of Hematology University of Schleswig Holstein Campus Kiel Kiel Germany

Department of Immunohematology and Blood Transfusion Leiden the Netherlands

Department of Laboratory Medicine Ghent University Hospital Ghent Belgium

Department of Medicine University of Salamanca Salamanca Spain

Department of Microbiology and Immunology Medical University of Silesia in Katowice Zabrze Poland

Department of Pediatric Hematology and Oncology Zabrze Medical University of Silesia in Katowice Katowice Poland

Institute of Biomedical Research of Salamanca Salamanca Spain

Laboratory for Medical Immunology Department of Immunology Erasmus MC University Medical Center Rotterdam Rotterdam The Netherlands

Pediatrics Institute IPPMG Faculty of Medicine Federal University of Rio de Janeiro Rio de Janeiro Brazil

Princess Máxima Center for Pediatric Oncology Utrecht The Netherlands

Tettamanti Research Center Pediatric Clinic University of Milano Bicocca Monza Italy

Translational and Clinical Research program Cancer Research Centre Cytometry Service NUCLEUS Salamanca Spain

Zobrazit více v PubMed

van Dongen JJ, van der Velden VH, Bruggemann M, Orfao A. Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies. Blood. 2015;125(26):3996–4009. PubMed PMC

van der Velden VHJ, Panzer‐Grümayer ER, Cazzaniga G, Flohr T, Sutton R, Schrauder A, et al. Optimization of PCR‐based minimal residual disease diagnostics for childhood acute lymphoblastic leukemia in a multi‐center setting. Leukemia. 2007;21(4):706–13. PubMed

Basso G, Veltroni M, Valsecchi MG, Dworzak MN, Ratei R, Silvestri D, et al. Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow. J Clin Oncol. 2009;27(31):5168–74. PubMed

Ribera J‐M, Morgades M, Ciudad J, Montesinos P, Esteve J, Genescà E, et al. Chemotherapy or allogeneic transplantation in high‐risk Philadelphia chromosome‐negative adult lymphoblastic leukemia. Blood. 2021;137(14):1879–94. PubMed

Theunissen P, Mejstrikova E, Sedek L, van der Sluijs‐Gelling AJ, Gaipa G, Bartels M, et al. Standardized flow cytometry for highly sensitive MRD measurements in B‐cell acute lymphoblastic leukemia. Blood. 2017;129(3):347–57. PubMed PMC

Przepiorka D, Ko C‐W, Deisseroth A, Yancey CL, Candau‐Chacon R, Chiu H‐J, et al. FDA approval: blinatumomab. Clin Cancer Res. 2015;21(18):4035–9. PubMed

Harris K, LaBelle JL, Bishop MR. Current status of CAR T cell therapy for leukemias. Curr Treat Options Oncol. 2021;22(7):62. PubMed

Kantarjian H, Stein A, Gökbuget N, Fielding AK, Schuh AC, Ribera J‐M, et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med. 2017;376(9):836–47. PubMed PMC

Libert D, Yuan CM, Masih KE, Galera P, Salem D, Shalabi H, et al. Serial evaluation of CD19 surface expression in pediatric B‐cell malignancies following CD19‐targeted therapy. Leukemia. 2020;34(11):3064–9. PubMed PMC

Mikhailova E, Semchenkova A, Illarionova O, Kashpor S, Brilliantova V, Zakharova E, et al. Relative expansion of CD19‐negative very‐early normal B‐cell precursors in children with acute lymphoblastic leukaemia after CD19 targeting by blinatumomab and CAR‐T cell therapy: implications for flow cytometric detection of minimal residual disease. Br J Haematol. 2021;193(3):602–12. PubMed

Mejstríková E, Hrusak O, Borowitz MJ, Whitlock JA, Brethon B, Trippett TM, et al. CD19‐negative relapse of pediatric B‐cell precursor acute lymphoblastic leukemia following blinatumomab treatment. Blood Cancer J. 2017;7(12):659. PubMed PMC

Sędek Ł, Bulsa J, Sonsala A, Twardoch M, Wieczorek M, Malinowska I, et al. The immunophenotypes of blast cells in B‐cell precursor acute lymphoblastic leukemia: how different are they from their normal counterparts? Cytometry B Clin Cytom. 2014;86(5):329–39. PubMed

Cherian S, Miller V, McCullouch V, Dougherty K, Fromm JR, Wood BL. A novel flow cytometric assay for detection of residual disease in patients with B‐lymphoblastic leukemia/lymphoma post anti‐CD19 therapy. Cytometry B Clin Cytom. 2018;94(1):112–20. PubMed